Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunitybio Inc
(NQ:
IBRX
)
3.930
+0.030 (+0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunitybio Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg
September 08, 2021
Johnson & Johnson (NYSE: JNJ) is reportedly considering running a COVID-19 vaccine booster trial in South Africa after its jab was used in a mass trial of...
Via
Benzinga
Exposures
COVID-19
ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives
September 07, 2021
From
ImmunityBio, Inc.
Via
Business Wire
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
September 05, 2021
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday...
Via
Benzinga
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
September 01, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion
August 16, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent
July 27, 2021
From
ImmunityBio, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
July 14, 2021
Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low....
Via
Benzinga
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
July 14, 2021
From
ImmunityBio, Inc.
Via
Business Wire
Cramer Weighs In On Cloudflare, MP Materials And More
July 08, 2021
On CNBC's "Mad Money Lightning Round," Jim Cramer said he should talk more about Cloudflare Inc (NYSE: NET) on the show because it has got a great security component...
Via
Benzinga
ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
June 28, 2021
From
ImmunityBio, Inc.
Via
Business Wire
FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer
June 15, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
June 10, 2021
From
ImmunityBio, Inc.
Via
Business Wire
60 Biggest Movers From Yesterday
June 08, 2021
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
June 07, 2021
Gainers Atossa Therapeutics (NASDAQ:ATOS)...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
June 03, 2021
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP
Via
Benzinga
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
May 25, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference
May 24, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021
May 20, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients
May 17, 2021
ImmunityBio Inc (NASDAQ: IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in...
Via
Benzinga
Exposures
Product Safety
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors
May 17, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients
May 04, 2021
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs
April 29, 2021
From
ImmunityBio, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
April 27, 2021
Gainers BioVie (NASDAQ:BIVI) shares rose 11.62% to $24.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 27.3K shares,...
Via
Benzinga
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications
April 22, 2021
From
ImmunityBio, Inc.
Via
Business Wire
Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses
April 08, 2021
ImmunityBio Inc (NASDAQ: IBRX) has reported initial data from the Phase 1 study evaluating its hAd5 COVID-19 vaccine candidate in healthy participants. Just...
Via
Benzinga
Exposures
COVID-19
ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
April 08, 2021
From
ImmunityBio, Inc.
Via
Business Wire
51 Biggest Movers From Yesterday
April 07, 2021
Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share. Romeo Power, Inc. (NYSE: RMO) climbed 59.6...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 06, 2021
Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 33.37% to $9.87 during Tuesday's regular session. As of 12:32 EST, this security is trading at a volume...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.